Fei Han

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Paul H. Bessette, A. Yang, O. Vasiljeva, 2013, Science Translational Medicine.

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway

P. Nuciforo, Rachel Kroe-Barrett, J. Capdevila, 2021, Molecular Cancer Therapeutics.

Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair.

R. Shao, Y. Zhen, B. Shang, 2014, Asian Pacific journal of cancer prevention : APJCP.

Hsp 90 Inhibitor Geldanamycin Enhances the Antitumor Efficacy of Enediyne Lidamycin in Association with Reduced DNA Damage Repair

R. Shao, Y. Zhen, B. Shang, 2014 .

Silencing eL31 suppresses the progression of colorectal cancer via targeting DEPDC1

Longlong Jia, Xiongfeng Li, Fei Han, 2022, Journal of Translational Medicine.

Succinylation and redox status in cancer cells

Jitian Li, Fei Han, X. Dai, 2022, Frontiers in Oncology.

Abstract 4570: Development of a proteolytically activatable EGFR Probody for cancer therapy.

A. Yang, O. Vasiljeva, D. Hostetter, 2013 .